Somewhat Favorable News Coverage Somewhat Unlikely to Impact Baxter International (BAX) Share Price
Media headlines about Baxter International (NYSE:BAX) have trended somewhat positive on Sunday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Baxter International earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 46.0630040965746 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Hospitals still grappling with IV fluid shortage – Seeking Alpha (seekingalpha.com)
- Baxter International Inc (BAX) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Second Lot Of Baxter’s Nexterone Recalled From Market (pharmpro.com)
- Baxter to Present at the 7th Annual Leerink Partners Global Healthcare Conference (finance.yahoo.com)
- Baxter International Inc.: Baxter Expands Voluntary Nationwide Recall to … (twst.com)
Shares of Baxter International (NYSE:BAX) traded up $0.81 during mid-day trading on Friday, reaching $70.01. The company had a trading volume of 3,525,083 shares, compared to its average volume of 2,840,000. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.22 and a current ratio of 2.80. The stock has a market capitalization of $38,140.00, a PE ratio of 37.84, a P/E/G ratio of 2.10 and a beta of 0.69. Baxter International has a 52 week low of $45.47 and a 52 week high of $70.02.
The business also recently declared a quarterly dividend, which was paid on Tuesday, January 2nd. Investors of record on Friday, December 1st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend was Thursday, November 30th. Baxter International’s dividend payout ratio is currently 34.59%.
Several research analysts have recently issued reports on BAX shares. Evercore ISI started coverage on Baxter International in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 price objective for the company. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 2nd. Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a research note on Wednesday, January 3rd. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $69.00 price objective for the company in a research note on Tuesday, October 10th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $65.00 price objective on shares of Baxter International in a research note on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $68.64.
In related news, SVP Giuseppe Accogli sold 28,641 shares of Baxter International stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Third Point Llc sold 5,000,000 shares of Baxter International stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $64.23, for a total value of $321,150,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,061,991 shares of company stock valued at $325,245,035. 0.05% of the stock is owned by company insiders.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.